With 1.81 million avg volume, 7 days are for Obsidian Energy Limited (NYSE:OBE)'s short sellers to cover OBE's short positions. Investors of record on Friday, October 13th will be issued a $0.265 dividend. The target implies a 2.01% spike from where the shares are now trading. It is down 48.14% since October 10, 2016 and is uptrending. A month ago, they told us to expect earnings of US$0.73 per share while three months ago their EPS consensus estimate was US$0.72. The Free Cash Flow Yield 5 Year Average of Abbott Laboratories (NYSE:ABT) is 0.03813.
Shares of Abbott Laboratories (NYSE:ABT) opened at 43.68 on Wednesday.
Abbott Laboratories (NYSE ABT) traded up 1.04% during midday trading on Tuesday, hitting $55.23. It has underperformed by 0.80% the S&P500.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. Concert Wealth Management Inc who had been investing in Abbott Labs for a number of months, seems to be bullish on the $96.25B market cap company. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The P/E Ratio for ABT is 77.46. The Company's Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.
According to Zacks brokerage recommendations, Abbott Laboratories (NYSE:ABT)'s Buy count is 2 and Strong Buy is 12 while the number of analysts recommending Sell and Strong Sell are 0 and 5, respectively. Therefore 61% are positive. Over the course of the a year ago ABT has set a 52-week high of $55.11 while the corresponding low set was $37.38. The stock's average target of $25.50 is -11.15% below today's ($28.7) share price. Whittier Trust Co. lifted its stake in shares of Abbott Laboratories by 1.7% during the first quarter.
10/04/2017 - Abbott Laboratories had its "buy" rating reiterated by analysts at Bank of America Merrill Lynch. The rating was maintained by Stifel Nicolaus with "Buy" on Thursday, July 20. Argus Research upgraded the shares of ABT in report on Friday, February 5 to "Buy" rating. Cowen & Co maintained the stock with "Buy" rating in Tuesday, August 15 report. Royal Bank of Canada reissued a "buy" rating on shares of Abbott Laboratories in a research report on Monday, May 15th. Adelante Capital Management Llc bought 190,556 shares as the company's stock rose 15.06% with the market. USB has a 1-week performance of 0.77%. It improved, as 27 investors sold WPC shares while 76 reduced holdings.
Several hedge funds and other institutional investors have recently made changes to their positions in the business.
07/10/2017 - Abbott Laboratories had its "equal-weight" rating reiterated by analysts at Morgan Stanley. The Girard Partners Ltd holds 123,505 shares with $8.51 million value, up from 114,634 last quarter. Wallace Cap Mgmt holds 0.03% or 4,133 shares in its portfolio. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Chicagobusiness.com and their article: "Like it or not, Abbott is stuck with this purchase" published on October 06, 2017 as well as Seekingalpha.com's news article titled: "Abbott Labs: Up, Up And Away" with publication date: September 28, 2017. Marshwinds Advisory has 1.53% invested in Abbott Laboratories (NYSE:ABT). Finally, Jefferies Group LLC reissued a "buy" rating and set a $51.00 price target (up from $50.00) on shares of Abbott Laboratories in a research report on Friday, May 12th. Burns J W Ny invested in 0.27% or 20,921 shares.
Adelante Capital Management Llc increased its stake in Marriott International (MAR) by 55.7% based on its latest 2017Q2 regulatory filing with the SEC. Daiwa Grp Incorporated has 55,241 shares for 0.02% of their portfolio. Brinker Capital holds 0.35% or 155,405 shares in its portfolio. Natl Pension reported 0.38% stake. It also reduced Chemed Corporation (NYSE:CHE) stake by 8,900 shares and now owns 240,600 shares.
Since January 1, 0001, it had 0 insider purchases, and 1 insider sale for $26,482 activity. 552 shares were sold by Watkin Jared, worth $26,482 on Thursday, June 15. 0 analysts gave its stock an Outperform rating. Abbott Laboratories experienced its Day High at -1.53%, with its Day Low of 12.30%. Also, the current price highlights a discount of 17.09% to analysts' high consensus price target. This estimate is provided by 16 analysts. On September 26, 2017, Daniel Gesua Sive Salvadori executed a direct buy involving 62460 shares.
WPX Energy, Inc. (NYSE:WPX) is another stock that is grabbing investors attention these days. On Tuesday, April 5 the stock rating was maintained by KeyBanc Capital Markets with "Overweight".
06/28/2017 - Guggenheim began new coverage on Abbott Laboratories giving the company a "buy" rating. The EPS growth in the running year displays a value of -58.60%.